Could SER-109 be an Answer for Recurrent C.Difficile Infection?

Update: 2022-02-22

Description

A phase 3, double-blind, randomized, placebo-controlled trial conducted to show superiority of SER-109 in reducing the risk of C. difficile infection recurrence up to 8 weeks after treatment.

Comments

In Channel

Ketamine for Sickle Cell Disease

2024-08-2813:02

Phenytoin for Tacrolimus Toxicity

2024-04-2514:00

Apixaban in Peripheral Artery Disease

2023-11-3010:30

Safety and Efficacy of Rezafungin

2023-07-2009:41

Lecanemab in the treatment of Alzheimer's Dementia

2023-04-1709:28

Yet Another Drug Shortage? Alternatives to Oxytocin

2022-10-1404:58

Could Intermittent Fasting be the Next Big Weight Loss Tool?

2022-06-2104:30

To Boost or not to Boost - That is the Question

2022-02-1105:38

Tirzepatide for Weight Loss in Diabetic Patients

2023-03-0608:53

Tirzepatide for Sleep Apnea

2024-07-2611:02

Excoriation Disorder

2024-05-2810:50

Atypical Antipsychotics and QT–prolongation

2024-02-2711:08

Safety and Efficacy of RSV Vaccines

2023-09-2709:59

Perioperative Duloxetine During Orthopedic Surgery for Pain Reduction

2023-06-1308:26

Can Evusheld Increase Cardiovascular Events?

2022-09-2604:48

A 4th Dose of the COVID-19 Vaccine

2022-04-2905:47

A Possible Alternative for Recurrent Urinary Tract Infections

2022-04-2105:43